Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts
Open accessPublished version of a preprint
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and causes serious health complications in individuals with and without type 2 diabetes (T2D). Early diagnosis of NAFLD is important, as this can help prevent irreversible damage to the liver and, ultimately, hepatocellular carcinomas. We sought to expand etiological understanding and develop a diagnostic tool for NAFLD using machine learning. METHODS AND FINDINGS: We utilized the baseline data from IMI DIRECT, a multicenter prospective cohort study of 3,029 European-ancestry adults recently diagnosed with T2D (n = 795) or at high risk of developing the disease (n = 2,234). Multi-omics (genetic, transcriptomic, proteomic, and metabolomic) and clinical (liver enzymes and other serological biomarkers, anthropometry, measures of beta-cell function, insulin sensitivity, and lifestyle) data comprised the key input variables. The models were trained on MRI-image-derived liver fat content (<5% or ≥5%) available for 1,514 participants. We applied LASSO (least absolute shrinkage and selection operator) to select features from the different layers of omics data and random forest analysis to develop the models. The prediction models included clinical and omics variables separately or in combination. A model including all omics and clinical variables yielded a cross-validated receiver operating characteristic area under the curve (ROCAUC) of 0.84 (95% CI 0.82, 0.86; p < 0.001), which compared with a ROCAUC of 0.82 (95% CI 0.81, 0.83; p < 0.001) for a model including 9 clinically accessible variables. The IMI DIRECT prediction models outperformed existing noninvasive NAFLD prediction tools. One limitation is that these analyses were performed in adults of European ancestry residing in northern Europe, and it is unknown how well these findings will translate to people of other ancestries and exposed to environmental risk factors that differ from those of the present cohort. Another key limitation of this study is that the prediction was done on a binary outcome of liver fat quantity (<5% or ≥5%) rather than a continuous one. CONCLUSIONS: In this study, we developed several models with different combinations of clinical and omics data and identified biological features that appear to be associated with liver fat accumulation. In general, the clinical variables showed better prediction ability than the complex omics variables. However, the combination of omics and clinical variables yielded the highest accuracy. We have incorporated the developed clinical models into a web interface (see: https://www.predictliverfat.org/) and made it available to the community. TRIAL REGISTRATION: ClinicalTrials.gov NCT03814915.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Pearson pairwise correlation matrix of clinical variables (data are inverse normal transformed) in the cohort combining participants with and without diabetes in IMI DIRECT (n = 1,049). The magnitude and direction of the correlation are reflected by the size (larger is stronger) and color (red is positive and blue is negative) of the circles, respectively. ActGLP1min0, concentration of fasting active GLP-1 in plasma; ALT, alanine transaminase; AST, aspartate transaminase; AST_ALT, AST to ALT ratio; BasalISR, insulin secretion at the beginning of the oral glucose tolerance test/mixed-meal tolerance test; BMI, body mass index; CHOI, total daily intake of dietary carbohydrates; Chol, total cholesterol; Clins, mean insulin clearance during the oral glucose tolerance test/mixed-meal tolerance test, calculated as (mean insulin secretion)/(mean insulin concentration); Clinsb, insulin clearance calculated from basal values as (insulin secretion)/(insulin concentration); DBP, mean diastolic blood pressure; FatI, total daily intake of dietary fats; FLI, fatty liver index; FibreI, total daily intake of dietary Association of Official Analytical Chemists (AOAC) fiber; GGTP, gamma-glutamyl transpeptidase; Glucagonmin0, fasting glucagon concentration; Glucose, fasting glucose from venous plasma samples; GlucoseSens, glucose sensitivity, slope of the dose–response relating insulin secretion to glucose concentration; HbA1c, hemoglobin A1C; HDL, fasting high-density lipoprotein cholesterol; IncGLP1min60, 1-hour GLP-1 increment; IncGlucagonmin60, 1-hour glucagon increment; Insulin, fasting insulin from venous plasma samples; LDL, fasting low-density lipoprotein cholesterol; Matsuda, insulin sensitivity index according to the method of Matsuda et al. [23]; MeanGlucose, mean glucose during the oral glucose tolerance test/mixed-meal tolerance test; MeanInsulin, mean insulin during the oral glucose tolerance test/mixed-meal tolerance test; MUFatI, daily intake of dietary monounsaturated fats; OGIS, oral glucose insulin sensitivity index according to the method of Mari et al. [24]; PA_intensity_0_48f, number of values in high-pass-filtered vector magnitude physical activity at ≥0 and ≤48; PA_intensity_154_389f, number of values in high-pass-filtered vector magnitude physical activity at ≥154 and ≤389; PA_intensity_389_9999f, number of values in high-pass-filtered vector magnitude physical activity at ≥389 and ≤9,999; PA_intensity_48_154f, number of values in high-pass-filtered vector magnitude physical activity at ≥48 and ≤154; PA_intensity_mean, mean high-pass-filtered vector magnitude physical activity intensity; PFR, potentiation factor ratio; ProteinI, total daily intake of dietary proteins; PUFatI, daily intake of dietary polyunsaturated fats; RateSens, rate sensitivity (parameter characterizing early insulin secretion); SatFatI, daily intake of dietary saturated fats; SBP, mean systolic blood pressure; Stumvoll, insulin sensitivity index according to the method of Stumvoll et al. [25]; SugarI, total daily intake of dietary; TEI, total daily energy intake based on validated multi-pass food habit questionnaire; TG, fasting triglycerides; TotalISR, integral of insulin secretion during the whole oral glucose tolerance test/mixed-meal tolerance test; TotGLP1min0, concentration of fasting total GLP-1 in plasma; TwoGlucose, 2-hour glucose after oral glucose tolerance test/mixed-meal tolerance test; TwoInsulin, 2-hour insulin; Waist_Hip, waist to hip ratio.](https://figures.cochat.ai/paper-figures/c6afde009f044f439bdf277ccb72f2cd/predicting-and-elucidating-the-etiology-of-fatty-liver-disease-a-machine-figure-1.jpg)




![Fig 6 Variable importance for the advanced model 14 with 185 omics and clinical input variables (clinical = 22, genetic = 23, transcriptomic = 93, exploratory proteomic = 22, and targeted metabolomic = 25). The y-axis shows the top 20 predictors in the model. The x-axis shows the variable importance calculated, via a permutation accuracy importance measure using random forest analysis, as the difference in prediction accuracy before and after the permutation for each variable scaled by the standard error. ALT, alanine transaminase; AST, aspartate transaminase; BasalISR, insulin secretion at the beginning of the oral glucose tolerance test/mixed-meal tolerance test; BMI, body mass index; Clins, mean insulin clearance during the oral glucose tolerance test/mixed-meal tolerance test calculated as (mean insulin secretion)/(mean insulin concentration); FLT3, fetal liver tyrosine kinase-3; Insulin, fasting insulin from venous plasma samples; MYLIP, myosin regulatory light chain interacting protein; OGIS, oral glucose insulin sensitivity index according to the method of Mari et al. [24]; TG, fasting triglycerides; TotGLP1min0, concentration of fasting total GLP-1 in plasma; TwoInsulin, 2-hour insulin after oral glucose tolerance test/mixed meal tolerance test.](https://figures.cochat.ai/paper-figures/137180b4880f4b5480756e69a65eead9/predicting-and-elucidating-the-etiology-of-fatty-liver-disease-a-machine-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the IMI-DIRECT study, Atabaki-Pasdar et al.93 identified several variables with high discriminative power for MASLD; those with the best performance were associated with lipids, i.e. PCs and glycerophospholipids, in particular ceramides, and included lipoprotein lipase proteins and the PNPLA3-148M gene variant.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 1×
“The penalty applied by λ can be any value from 0 to positive infinity and is determined through a cross-validation step [26].”
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927 · cited 1×
“LASSO was conducted with package glmnet in R [28] with a 10-fold cross-validation step for defining the λ parameter that resulted in the minimum value for the mean square error of the regression model.”
MethodTissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Self-citationSudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“The UK Biobank cohort [38] was used to validate the clinical prediction models (models 1 and 2) derived using IMI DIRECT data (UK Biobank application ID: 18274).”
MethodYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
An Introduction to Kernel and Nearest-Neighbor Nonparametric Regression
Altman, N. S. (1992) · The American Statistician · doi:10.1080/00031305.1992.10475879 · Cited by 5,708 · cited 1×
“We used k-nearest neighbor [22] imputation with k equal to 10 as a means to reduce the loss of sample size, but found that this did not materially improve predictive power in subsequent analyses, so we decided not to include these imputed data.”
MethodMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“[23]; MeanGlucose, mean glucose during the oral glucose tolerance test/mixed-meal tolerance test; MeanInsulin, mean insulin during the oral glucose tolerance test/mixed-meal tolerance test; MUFatI, daily intake of dietary monounsaturated fats; OGIS, oral glucose insulin sensitivity index according to the method of Mar…”
MethodBias in random forest variable importance measures: Illustrations, sources and a solution
Strobl, C., Boulesteix, A.-L., Zeileis, A., & Hothorn, T. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-25 · Cited by 3,688
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 3×
“The FLI is one of the most well-established and commonly used fatty liver indices, initially developed using ultrasound-derived hepatic steatosis data [34].”
BackgroundMethodNon-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“This is especially important because if NAFLD is detected early, treatment through lifestyle interventions can be highly effective [39].”
BackgroundAssarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Bucht Thorsen, S., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., Edfeldt, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095192 · Cited by 1,874
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Lee, J.-H., Kim, D., Kim, H. J., Lee, C.-H., Yang, J. I., Kim, W., Kim, Y. J., Yoon, J.-H., Cho, S.-H., Sung, M.-W., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.08.002 · Cited by 1,621 · cited 17×
“Better discrimination can be obtained by incorporating additional serological and hemostatic measures, which is the case with NAFLD-LFS [14], the SteatoTest [42], and the HSI [35], for example.”
BackgroundMethodInfluentialNoninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494 · cited 1×
“To address this gap, several liver fat prediction indices have been developed, but none of these has sufficiently high predictive ability to be considered a gold standard [12].”
BackgroundNon-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424 · cited 1×
“Growing evidence also links an increased risk of cardiovascular events with NAFLD [6,7].”
BackgroundUse of the oral glucose tolerance test to assess insulin release and insulin sensitivity.
Stumvoll, M., Mitrakou, A., Pimenta, W., Jenssen, T., Yki-Järvinen, H., Van Haeften, T., Renn, W., & Gerich, J. (2000) · Diabetes Care · doi:10.2337/diacare.23.3.295 · Cited by 1,042 · cited 1×
“[25]; SugarI, total daily intake of dietary; TEI, total daily energy intake based on validated multi-pass food habit questionnaire; TG, fasting triglycerides; TotalISR, integral of insulin secretion during the whole oral glucose tolerance test/mixed-meal tolerance test; TotGLP1min0, concentration of fasting total GLP-…”
MethodGenetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971 · cited 1×
“Reassuringly, several of the features that ranked highest have been previously described for their association with liver fat content or closely related traits; these include PNPLA3 gene variants [44,51], fetal liver tyrosine kinase-3 (FLT3) transcripts [52], IGFBP1 [53–55] and lipoprotein lipase (Lpl) [56] proteins,…”
BackgroundA Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test
Mari, A., Pacini, G., Murphy, E., Ludvik, B., & Nolan, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.539 · Cited by 806 · cited 6×
“[24]; OGTT, oral glucose tolerance test; PA_intensity_mean, mean high-pass-filtered vector magnitude physical activity intensity; SBP, systolic blood pressure; TotGLP1min0, concentration of fasting total GLP-1 in plasma.”
BackgroundMethodInfluentialSelf-citationPrediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L. M., Lundbom, N., Rissanen, A., Ridderstråle, M., Groop, L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.005 · Cited by 804
Self-citationThe epidemiology of non‐alcoholic fatty liver disease
Bellentani, S. (2017) · Liver International · doi:10.1111/liv.13299 · Cited by 606
Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., & the LIDO Study Group (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12963 · Cited by 500 · cited 11×
“Better discrimination can be obtained by incorporating additional serological and hemostatic measures, which is the case with NAFLD-LFS [14], the SteatoTest [42], and the HSI [35], for example.”
BackgroundInfluentialUhlén, M., Karlsson, M. J., Hober, A., Svensson, A.-S., Scheffel, J., Kotol, D., Zhong, W., Tebani, A., Strandberg, L., Edfors, F., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaz0274 · Cited by 495 · cited 1×
“For exploratory proteomics, the most important variables were proteins secreted into the blood, expressed by the liver as well as those leaking from the blood cells [60].”
BackgroundSelf-citationInsulin resistance, inflammation, and non-alcoholic fatty liver disease
Tilg, H., & Moschen, A. R. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.08.005 · Cited by 473
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
Gaggini, M., Carli, F., Rosso, C., Buzzigoli, E., Marietti, M., Della Latta, V., Ciociaro, D., Abate, M. L., Gambino, R., Cassader, M., et al. (2018) · Hepatology · doi:10.1002/hep.29465 · Cited by 465
Epidemiology and natural history of non-alcoholic fatty liver disease
Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D., & Younossi, Z. M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.012 · Cited by 433
Araújo, A. R., Rosso, N., Bedogni, G., Tiribelli, C., & Bellentani, S. (2018) · Liver International · doi:10.1111/liv.13643 · Cited by 401 · cited 1×
“However, simple steatosis is usually asymptomatic, and many patients only come to the attention of hepatologists when serious complications arise [40].”
BackgroundZhan, X., Hu, Y., Li, B., Abecasis, G. R., & Liu, D. J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw079 · Cited by 396
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
Poynard, T., Ratziu, V., Naveau, S., Thabut, D., Charlotte, F., Messous, D., Capron, D., Abella, A., Massard, J., Ngo, Y., et al. (2005) · Comparative Hepatology · doi:10.1186/1476-5926-4-10 · Cited by 368 · cited 1×
“Better discrimination can be obtained by incorporating additional serological and hemostatic measures, which is the case with NAFLD-LFS [14], the SteatoTest [42], and the HSI [35], for example.”
MethodNon-alcoholic fatty liver disease
Sattar, N., Forrest, E., & Preiss, D. (2014) · BMJ · doi:10.1136/bmj.g4596 · Cited by 325
Insulin-Like Growth Factor (IGF) System in Liver Diseases
Adamek, A., & Kasprzak, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051308 · Cited by 284
Metabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Type 2 diabetes as a disease of ectopic fat?
Sattar, N., & Gill, J. M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0123-4 · Cited by 220
Methodology series module 5: Sampling strategies
Setia, M. (2016) · Indian Journal of Dermatology · doi:10.4103/0019-5154.190118 · Cited by 218 · cited 1×
“Stratified random sampling [27] based on the outcome variable was undertaken in order to preserve the distribution of the liver fat categories in the 2 feature selection and model generation sets.”
MethodYounossi, Z. M., Tampi, R., Priyadarshini, M., Nader, F., Younossi, I. M., & Racila, A. (2019) · Hepatology · doi:10.1002/hep.30254 · Cited by 212
Mahfood Haddad, T., Hamdeh, S., Kanmanthareddy, A., & Alla, V. M. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.033 · Cited by 182
Whole body fat: Content and distribution
Thomas, E. L., Fitzpatrick, J. A., Malik, S. J., Taylor-Robinson, S. D., & Bell, J. D. (2013) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2013.04.001 · Cited by 168 · cited 11×
“The same protocol and procedure have been used to quantify MRI-derived liver fat in IMI DIRECT and UK Biobank [18].”
MethodInfluentialSelf-citationCharacterisation of liver fat in the UK Biobank cohort
Wilman, H. R., Kelly, M., Garratt, S., Matthews, P. M., Milanesi, M., Herlihy, A., Gyngell, M., Neubauer, S., Bell, J. D., Banerjee, R., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172921 · Cited by 159 · cited 11×
“The same protocol and procedure have been used to quantify MRI-derived liver fat in IMI DIRECT and UK Biobank [18].”
MethodInfluentialSelf-citationPerakakis, N., Polyzos, S. A., Yazdani, A., Sala-Vila, A., Kountouras, J., Anastasilakis, A. D., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154005 · Cited by 137
Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease
Motamed, N., Sohrabi, M., Ajdarkosh, H., Hemmasi, G., Maadi, M., Sayeedian, F. S., Pirzad, R., Abedi, K., Aghapour, S., Fallahnezhad, M., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i10.3023 · Cited by 119 · cited 1×
“Though commonly used for liver fat prediction, the FLI has a similar discriminative ability as waist circumference alone [41].”
BackgroundAldo, P. B., Marusov, G., Svancara, D., David, J., & Mor, G. (2016) · American Journal of Reproductive Immunology · doi:10.1111/aji.12512 · Cited by 104
EFS: an ensemble feature selection tool implemented as R-package and web-application
Neumann, U., Genze, N., & Heider, D. (2017) · BioData Mining · doi:10.1186/s13040-017-0142-8 · Cited by 94 · cited 1×
“In addition, we used the ensemble feature selection (EFS) method to determine the normalized importance value of all features [31].”
MethodMetabolomic biomarkers correlating with hepatic lipidosis in dairy cows
Imhasly, S., Naegeli, H., Baumann, S., von Bergen, M., Luch, A., Jungnickel, H., Potratz, S., & Gerspach, C. (2014) · BMC Veterinary Research · doi:10.1186/1746-6148-10-122 · Cited by 93 · cited 1×
“C42), glycerophospholipids, and valine were amongst the highest-ranked metabolites that are known for their correlation with NAFLD and metabolic disorders [58,59].”
BackgroundCastera, L. (2018) · Liver International · doi:10.1111/liv.13658 · Cited by 83 · cited 1×
“To date, several prediction models have been developed to facilitate the diagnosis of steatosis (thoroughly reviewed elsewhere [13]).”
MethodNon-invasive assessment of NAFLD as systemic disease—A machine learning perspective
Canbay, A., Kälsch, J., Neumann, U., Rau, M., Hohenester, S., Baba, H. A., Rust, C., Geier, A., Heider, D., & Sowa, J.-P. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214436 · Cited by 82 · cited 5×
“These include tests utilizing genetic data such as FibroGENE for staging liver fibrosis [46], and tests using metabolomic data derived from liver tissue to differentiate simple hepatitis from NASH [47], as well as a multi-component NAFLD classifier using genomic, proteomic, and phenomic data [45].”
MethodInfluentialFibroGENE: A gene-based model for staging liver fibrosis
Eslam, M., Hashem, A. M., Romero-Gomez, M., Berg, T., Dore, G. J., Mangia, A., Chan, H. L. Y., Irving, W. L., Sheridan, D., Abate, M. L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.008 · Cited by 75
Highly Multiplexed Antibody Suspension Bead Arrays for Plasma Protein Profiling
Drobin, K., Nilsson, P., & Schwenk, J. M. (2013) · Methods in molecular biology · doi:10.1007/978-1-4614-7209-4_8 · Cited by 67 · cited 1×
“In addition, protein data were generated by single-binder assays using highly multiplexed suspension bead arrays [21].”
MethodSelf-citationChen, Y., Huang, H., Xu, C., Yu, C., & Li, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010021 · Cited by 66 · cited 1×
“Reassuringly, several of the features that ranked highest have been previously described for their association with liver fat content or closely related traits; these include PNPLA3 gene variants [44,51], fetal liver tyrosine kinase-3 (FLT3) transcripts [52], IGFBP1 [53–55] and lipoprotein lipase (Lpl) [56] proteins,…”
Backgroundfor the DIRECT Consortium, Koivula, R. W., Heggie, A., Barnett, A., Cederberg, H., Hansen, T. H., Koopman, A. D., Ridderstråle, M., Rutters, F., Vestergaard, H., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3216-x · Cited by 60
Self-citationWood, G. C., Chu, X., Argyropoulos, G., Benotti, P., Rolston, D., Mirshahi, T., Petrick, A., Gabrielson, J., Carey, D. J., DiStefano, J. K., et al. (2017) · Scientific Reports · doi:10.1038/srep43238 · Cited by 56
A systematic review of the present and future of non-alcoholic fatty liver disease
Lucas, C., Lucas, G., Lucas, N., Krzowska-Firych, J., & Tomasiewicz, K. (2018) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2018.78120 · Cited by 52
Non-alcoholic fatty liver disease: a narrative review of genetics
Christopher, J., Zemin, Y., & Z., G. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.32.20180045 · Cited by 45 · cited 1×
“Reassuringly, several of the features that ranked highest have been previously described for their association with liver fat content or closely related traits; these include PNPLA3 gene variants [44,51], fetal liver tyrosine kinase-3 (FLT3) transcripts [52], IGFBP1 [53–55] and lipoprotein lipase (Lpl) [56] proteins,…”
BackgroundIGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD – a pilot study
Hagström, H., Stål, P., Hultcrantz, R., Brismar, K., & Ansurudeen, I. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1379556 · Cited by 44
Koivula, R. W., Forgie, I. M., Kurbasic, A., Viñuela, A., Heggie, A. J., Giordano, G. N., Hansen, T. H., Hudson, M., Koopman, A. D. M., Rutters, F., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4906-1 · Cited by 40
Self-citationPhosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD
Petäjä, E. M., Zhou, Y., Havana, M., Hakkarainen, A., Lundbom, N. M. I., Ihalainen, J., & Yki‐Järvinen, H. (2016) · Scientific Reports · doi:10.1038/srep24740 · Cited by 29
The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease
Baranova, A. V., Liotta, L. A., Petricoin, E. F., & Younossi, Z. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.003 · Cited by 28
Al‐Fayoumi, S., Hashiguchi, T., Shirakata, Y., Mascarenhas, J. O., & Singer, J. W. (2018) · Journal of Experimental Pharmacology · doi:10.2147/jep.s150729 · Cited by 27 · cited 1×
“Reassuringly, several of the features that ranked highest have been previously described for their association with liver fat content or closely related traits; these include PNPLA3 gene variants [44,51], fetal liver tyrosine kinase-3 (FLT3) transcripts [52], IGFBP1 [53–55] and lipoprotein lipase (Lpl) [56] proteins,…”
BackgroundKatsiki, N., Gastaldelli, A., & Mikhailidis, D. P. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154010 · Cited by 26
Koch, M., Freitag‐Wolf, S., Schlesinger, S., Borggrefe, J., Hov, J. R., Jensen, M. K., Pick, J., Markus, M. R. P., Höpfner, T., Jacobs, G., et al. (2017) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2017.43 · Cited by 23 · cited 1×
“C42), glycerophospholipids, and valine were amongst the highest-ranked metabolites that are known for their correlation with NAFLD and metabolic disorders [58,59].”
BackgroundSelf-citation
Cited by
Asnicar, F., Berry, S. E., Valdes, A. M., Nguyen, L. H., Piccinno, G., Drew, D. A., Leeming, E., Gibson, R., Le Roy, C., Khatib, H. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01183-8 · Cited by 995
Self-citationNoninvasive proteomic biomarkers for alcohol-related liver disease
Niu, L., Thiele, M., Geyer, P. E., Rasmussen, D. N., Webel, H. E., Santos, A., Gupta, R., Meier, F., Strauss, M., Kjaergaard, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01850-y · Cited by 309
Self-citationInter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274
“The IMI-DIRECT analysis highlighted circulating IGFBP1, IGFBP2, CXCL1 and the TNF super-family member CD30 (TNFRSF8) as predictors of (pre)T2DM-related NAFLD 237 .”
BackgroundMethodLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Ghosh, S., Zhao, X., Alim, M., Brudno, M., & Bhat, M. (2024) · Gut · doi:10.1136/gutjnl-2023-331740 · Cited by 128
“34 In their multiomics study, Atabaki-Pasdar et al 43 found that integrating genetic, transcriptomic, proteomic and metabolomic with clinical variables yielded better performance (AUROC 0.84) compared with using clinical variables alone (AUROC 0.82) in predicting liver fat quantity.”
Influential
Metadata
- Authors
- Atabaki-Pasdar, N., Ohlsson, M., Viñuela, A., Frau, F., Pomares-Millan, H., Haid, M., Jones, A. G., Thomas, E. L., Koivula, R. W., Kurbasic, A., Mutie, P. M., Fitipaldi, H., Fernandez, J., Dawed, A. Y., Giordano, G. N., Forgie, I. M., McDonald, T. J., Rutters, F., Cederberg, H., Chabanova, E., Dale, M., Masi, F. D., Thomas, C. E., Allin, K. H., Hansen, T. H., Heggie, A., Hong, M.-G., Elders, P. J. M., Kennedy, G., Kokkola, T., Pedersen, H. K., Mahajan, A., McEvoy, D., Pattou, F., Raverdy, V., Häussler, R. S., Sharma, S., Thomsen, H. S., Vangipurapu, J., Vestergaard, H., ‘t Hart, L. M., Adamski, J., Musholt, P. B., Brage, S., Brunak, S., Dermitzakis, E., Frost, G., Hansen, T., Laakso, M., Pedersen, O., Ridderstråle, M., Ruetten, H., Hattersley, A. T., Walker, M., Beulens, J. W. J., Mari, A., Schwenk, J. M., Gupta, R., McCarthy, M. I., Pearson, E. R., Bell, J. D., Pavo, I., & Franks, P. W.
- Affiliations
- Lund University (SE)
- University of Geneva (CH)
- Sanofi (Germany) (DE)
- Helmholtz Munich (DE)
- University of Exeter (GB)
- University of Westminster (GB)
- University of Dundee (GB)
- Amsterdam Public Health (NL)
- Helsinki University Hospital (FI)
- Herlev Hospital (DK)
- Science for Life Laboratory (SE)
- Technical University of Denmark (DK)
- University of Copenhagen (DK)
- Newcastle University (GB)
- University of Eastern Finland (FI)
- Centre for Human Genetics (GB)
- Inserm (FR)
- National University of Singapore (SG)
- Sanofi (France) (FR)
- Imperial College London (GB)
- Novo Nordisk (Denmark) (DK)
- University Medical Center Utrecht (NL)
- National Academies of Sciences, Engineering, and Medicine (US)
- Eli Lilly (United States) (US)
- Harvard University (US)
- Corresponding author
- Ohlsson, Mattias
- Viñuela, Ana
- Frau, Francesca
- Haid, Mark
- Jones, Angus G.
- Thomas, E. Louise
- Koivula, Robert W.
- Kurbasic, Azra
- Mutie, Pascal M.
- Fitipaldi, Hugo
- Fernandez, Juan
- Dawed, Adem Y.
- Giordano, Giuseppe N.
- Forgie, Ian M.
- McDonald, Timothy J.
- Rutters, Femke
- Cederberg, Henna
- Chabanova, Elizaveta
- Dale, Matilda
- Masi, Federico De
- Thomas, Cecilia Engel
- Allin, Kristine H.
- Hansen, Tue H.
- Heggie, Alison
- Hong, Mun-Gwan
- Elders, Petra J. M.
- Kennedy, Gwen
- Kokkola, Tarja
- Pedersen, Helle Krogh
- Mahajan, Anubha
- McEvoy, Donna
- Raverdy, Violeta
- Häussler, Ragna S.
- Sharma, Sapna
- Thomsen, Henrik S.
- Vangipurapu, Jagadish
- Vestergaard, Henrik
- Adamski, Jerzy
- Musholt, Petra B.
- Brunak, Søren
- Dermitzakis, Emmanouil
- Frost, Gary
- Hansen, Torben
- Laakso, Markku
- Pedersen, Oluf
- Ridderstråle, Martin
- Ruetten, Hartmut
- Hattersley, Andrew T.
- Walker, Mark
- Beulens, Joline W. J.
- Mari, Andrea
- Schwenk, Jochen M.
- Gupta, Ramneek
- McCarthy, Mark I.
- Pearson, Ewan R.
- Bell, Jimmy D.
- Pavo, Imre
- Franks, Paul W.
- ORCID
- Atabaki-Pasdar, Naeimeh
- Ohlsson, Mattias
- Viñuela, Ana
- Frau, Francesca
- Pomares-Millan, Hugo
- Haid, Mark
- Jones, Angus G.
- Thomas, E. Louise
- Koivula, Robert W.
- Kurbasic, Azra
- Mutie, Pascal M.
- Fitipaldi, Hugo
- Fernandez, Juan
- Dawed, Adem Y.
- Giordano, Giuseppe N.
- Forgie, Ian M.
- McDonald, Timothy J.
- Rutters, Femke
- Cederberg, Henna
- Chabanova, Elizaveta
- Dale, Matilda
- Masi, Federico De
- Thomas, Cecilia Engel
- Allin, Kristine H.
- Hansen, Tue H.
- Heggie, Alison
- Hong, Mun-Gwan
- Elders, Petra J. M.
- Kennedy, Gwen
- Kokkola, Tarja
- Pedersen, Helle Krogh
- Mahajan, Anubha
- McEvoy, Donna
- Raverdy, Violeta
- Häussler, Ragna S.
- Sharma, Sapna
- Thomsen, Henrik S.
- Vangipurapu, Jagadish
- Vestergaard, Henrik
- ‘t Hart, Leen M.
- Adamski, Jerzy
- Musholt, Petra B.
- Brage, Soren
- Brunak, Søren
- Dermitzakis, Emmanouil
- Frost, Gary
- Hansen, Torben
- Laakso, Markku
- Pedersen, Oluf
- Ridderstråle, Martin
- Hattersley, Andrew T.
- Walker, Mark
- Beulens, Joline W. J.
- Mari, Andrea
- Schwenk, Jochen M.
- Gupta, Ramneek
- McCarthy, Mark I.
- Pearson, Ewan R.
- Bell, Jimmy D.
- Pavo, Imre
- Franks, Paul W.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-06-19
- Volume
- 17
- Issue
- 6
- Pages
- e1003149
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC7304567
- OpenAlex
- W3035784389
- Cited by
- 97
- References
- 60
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 19 · 2023: 10 · 2022: 16 · 2021: 20 · 2020: 2
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Medicine (publishedVersion, public-domain)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, public-domain)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- WestminsterResearch (University of Westminster) (acceptedVersion, public-domain)
- HAL (submittedVersion, public-domain)
- Leiden Repository (Leiden University) (submittedVersion, other-oa)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion, public-domain)
- National University of Singapore (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Työväentutkimus Vuosikirja (submittedVersion)
- CNR ExploRA (submittedVersion, other-oa)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, public-domain)
- Lund University Publications (Lund University) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, public-domain)
- Leiden Repository (Leiden University) (submittedVersion, public-domain)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, public-domain)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Apollo (public-domain)
- Funders
- Innovative Medicines Initiative (115317 (DIRECT))
- Henning och Johan Throne-Holsts
- Hans Werthén
- Swedish Foundation for Strategic Research
- European Research Council (ERC-2015-CoG - 681742_NASCENT)
- Novo Nordisk Foundation (NNF18OC0031650, NNF17OC0027594, NNF14CC0001)
- NIHR clinical senior lecturer fellowship
- Wellcome Trust Senior Investigator
- NIHR Exeter Clinical Research Facility
- Science for Life Laboratory
- Knut and Alice Wallenberg Foundation
- Erling-Persson Foundation
- Wellcome (090532, 098381, 106130, 203141, 212259)
- NIH (U01-DK105535)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, liver fat, multi-omics, genetic biomarkers, transcriptomics, proteomics, metabolomics, LASSO feature selection, random forest, non-invasive diagnosis, beta-cell function, insulin sensitivity
- MeSH terms
- Machine Learning, Fatty Liver, Female, Humans, Male, Middle Aged, Prospective Studies, Reproducibility of Results, Models, Statistical, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.